Madelyn Elizabeth Burkart MD
Hematology/Oncology
Assistant Professor of Hematology/Oncology
Join to view full profile
1 Medical Center BlvdWinston-Salem, NC 27157
Dr. Burkart is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Madelyn Burkart is an internist in Winston Salem, NC and is affiliated with Atrium Wake Forest Baptist. She received her medical degree from Wake Forest School of Medicine of Wake Forest Baptist Medical Center and has been in practice 0 years. She specializes in hematology/oncology and is experienced in hematology, oncology, and hospitalist medicine. She has more than 40 publications and over 500 citings.
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2020 - 2032- McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2016 - 2019
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2016
University of North Carolina at Chapel HillBS, Biological Psychology
Certifications & Licensure
NC State Medical License 2023 - 2027
IL State Medical License 2018 - 2023
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Alpha Omega Alpha
Publications & Presentations
PubMed
- Clinical and sociodemographic predictors of intensive care unit admission following chemotherapy in acute myeloid leukemia.Ivy E Abraham, Garth H Rauscher, Jerry Luo, Sarah Monick, Madelyn Burkart
Haematologica. 2026-07-01 - 3 citationsImpact of modernizing eligibility criteria on enrollment and representation in acute myeloid leukemia clinical trials.Andrew Hantel, Yating Wang, Angel Cronin, Irum Khan, Ivy Abraham
Blood. 2026-02-05 - 4 citationsAssessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.Reid Shaw, James J Yoon, Hannah Johnston, Marta B Davidson, Alexa J Siddon
Blood Advances. 2025-05-27
Abstracts/Posters
- Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...Madelyn Burkart, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment FailureMadelyn Burkart, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell LymphomaMadelyn Burkart, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
